TL;DR — The ACAAI 2026 Annual Scientific Meeting runs November 12–16, 2026 at the Phoenix Convention Center, with the theme "Building Bridges for the Future." About 3,000 attendees — primarily community and private-practice allergists — and 80+ exhibitors. Roughly 55% of attendees have purchasing authority, and they skew community practice rather than academic, which makes ACAAI a strong fit for direct-to-physician sales of allergy diagnostics, immunotherapy delivery, biologics, and practice management software. Booth costs land between $5,500 and $11,000 all-in for a standard 10x10. Win it by booking pre-show meetings with target practices, leading with workflow ROI rather than KOL endorsements, and treating Phoenix as the front door to a Q4-Q1 community-practice buying cycle.

What ACAAI Is — and Why Phoenix 2026 Matters

The ACAAI Annual Scientific Meeting is the flagship event of the American College of Allergy, Asthma & Immunology, the larger of the two community-practice-facing allergy and immunology associations in the United States. Where AAAAI (the American Academy of Allergy, Asthma & Immunology) draws an academic and research-oriented audience, ACAAI is built for the allergist who owns a practice, runs a clinic, or sees patients five days a week. That distinction is the whole reason ACAAI deserves its own line item on a medical device or pharmaceutical conference budget.

ACAAI 2026 lands at the Phoenix Convention Center November 12–16, 2026 with the theme "Building Bridges for the Future." Phoenix is an accessible, mid-cost convention city for both vendors and attendees, and the November timing places the meeting at the front edge of the Q4-Q1 community-practice buying window — when private-practice allergists finalize capital purchases for the next calendar year and choose new immunotherapy, diagnostic, or practice management partners before benefits and contracts reset.

Three thousand attendees and 80+ exhibitors makes ACAAI a mid-scale conference by raw count, but the audience composition is what drives ROI. Community allergists, fellows, nurses, physician assistants, and practice managers walk this floor — and roughly 55% report direct purchasing authority. That is a higher purchase-decision concentration than most large clinical meetings, where attendance is dominated by residents, students, and academic faculty without buying power.

ACAAI 2026: The Numbers You Need

The five-comp-badges-per-100-sqft policy is unusually generous — most clinical conferences cap at one to three badges per equivalent footprint. That gives smaller exhibitors real flexibility to staff a 10x10 with a senior rep, a clinical specialist, and a meeting closer without paying for additional registration. It is one of the details that quietly improves ACAAI's ROI math compared to bigger meetings.

Pre-Conference Strategy: Build a Practice-Level Target List

The vendors who win ACAAI do most of their selling before they reach Phoenix. Community allergists do not have the calendar elasticity of academic faculty — they are seeing patients up until the day they fly out, and they are flying home to a full schedule the Monday after. If you want serious meeting time on the floor, you book it weeks in advance.

Build a target practice list by mid-September. Pull every allergy practice you have ever sold into, plus the top 250 community allergy groups in your sales geography. Prioritize multi-physician practices, practices that bill significant immunotherapy volume, and groups that have recently expanded to new locations or new service lines. Aim for a target list of 60–100 named practices with the specific allergists or practice managers you want to meet.

Run a four-touch outreach sequence starting six weeks out. The cadence that consistently produces booked meetings: a personalized email referencing the practice's specialty mix or a recent expansion, a LinkedIn connection request from your sales rep, a value-led second email (clinical update, billing/coding insight, peer case study from a similar-sized practice), and a calendar link with two or three specific meeting windows during the show. For deeper pre-show playbooks, our pre-conference email campaigns guide walks through subject-line patterns, send timing, and templates that hold up across allergy and other community-practice specialties.

Use the official ACAAI sponsorship and ad inventory. ACAAI offers paid sponsorship of the Annual Meeting Program Guide, mobile app, and pre-show attendee communications. The pre-show attendee email list is a one-shot, high-leverage opportunity to plant a reason to visit your booth. Smaller exhibitors often skip these because they look expensive on a per-impression basis, but for a target audience this concentrated, the per-qualified-lead math usually wins.

Booth Design and Messaging for Community Allergists

Community allergists are not academic researchers. They do not respond to the dense, citation-heavy clinical booths that work at AAAAI. They respond to evidence that your product fits their workflow, helps them bill correctly, and improves the patient experience without adding labor to a practice that is already short-staffed.

Build your booth around three zones. Workflow zone: physical demonstration of how your device, software, or biologic fits into a typical allergy practice day — patient flow, charting, billing, and reimbursement. Evidence zone: a tight selection of clinical and economic evidence focused on outcomes the community allergist cares about (patient adherence, in-office revenue, time savings) rather than mechanism-of-action depth. Conversation zone: a semi-private table where reps can run pricing, contract, and onboarding conversations with practice managers and physician owners.

Static graphics should answer the four questions every community allergist asks within 30 seconds of approaching the booth: How does this fit my workflow? What is the reimbursement and billing story? What is the patient experience? What is the all-in cost in year one? If your booth signage doesn't answer those questions before a rep opens their mouth, you are losing qualified traffic to the booth across the aisle that does. Our medical conference booth design playbook goes deeper on zone layouts and signage hierarchy.

On-Site Tactics: Education, Demos, and Practice-Level Sales

ACAAI attendees come for continuing medical education and for hands-on exposure to products they may actually buy in the next 90 days. The companies that earn the most floor traffic are the ones whose booths function as mini-classrooms — short, scheduled, billing-aware sessions that allergists can use back at their practice. A 15-minute session on a recent CPT code change for allergy testing, delivered by a credentialed coding expert, will out-pull a slick product demo every time.

Treat practice-level sales conversations differently than walk-up lead capture. A community allergist who is six months into evaluating a new immunotherapy delivery system for a four-physician practice does not want a badge scan and a generic follow-up drip. They want to sit down with your senior rep, your clinical specialist, and ideally your customer reference from a similar-sized practice, and have a 30-minute conversation about training, onboarding timeline, and reimbursement risk. Block out structured calendar slots in advance for these conversations and protect them from being interrupted by walk-up traffic.

For walk-up leads, use a tiered qualification approach. Tier 1 is owner-physicians and practice managers from groups on your target list — these get same-day calendar invites for either Saturday evening or a follow-up call within five business days. Tier 2 is qualified allergists without immediate buying authority — these enter a structured nurture sequence built around clinical and billing updates. Tier 3 is general traffic, residents, and fellows — these get a single product overview email and exit your active funnel within 30 days unless they re-engage.

Post-ACAAI Follow-Up: Converting Q4-Q1 Buying Windows

Community allergy practices buy on different timelines than health systems. Office-level capital purchases often close in 30–90 days once the practice owner has committed, but they require fast, organized follow-up — and they are frequently lost to faster competitors who follow up the Monday after the show while your team is still triaging badge scans on Wednesday.

The single most common post-ACAAI mistake is treating leads as a long-cycle health system pipeline rather than a 90-day community practice pipeline. Practice owners make decisions quickly when they have decided. The vendor that lands the first onsite training, the first contract draft, or the first reference call within five business days of the show wins disproportionately often. For a deeper post-show framework, our post-conference follow-up playbook covers cadence, segmentation, and CRM workflows that translate directly to allergy meetings.

Build your follow-up around the practice's actual decision calendar, not your sales calendar. A practice that is in active evaluation for a new allergy testing platform needs daily-cadence touches in the first two weeks after the show, then a structured nurture if they do not move. A practice that is six months out from a build-out or new location needs scheduled touches at design, build, and pre-launch milestones. Map every post-ACAAI lead to a specific decision window and time your touches accordingly.

Common Mistakes Vendors Make at ACAAI

Treating ACAAI like AAAAI. Booth design, messaging, and staffing built for an academic audience falls flat with community allergists. The aesthetic, the clinical depth, and the proof points are all different — and the cost of getting this wrong is five days of foot traffic that never converts.

Ignoring the practice manager. The allergist may be the prescribing decision-maker, but the practice manager controls the contract, the implementation timeline, and frequently the vendor short list. Booths that talk only to physicians lose deals to booths that engage practice managers as a parallel buying audience. Build out a track of content, demos, and conversations explicitly aimed at practice managers and office administrators.

Underinvesting in pre-show meetings. ACAAI is small enough that pre-booked meetings dominate floor time. Vendors who plan to "see who shows up" leave Phoenix with badge scans they will never close. Vendors who arrive with 30+ pre-booked meetings on the calendar leave with active pipeline.

Generic clinical messaging. Allergy and immunology has unusually specific clinical and reimbursement detail — CPT codes, prior authorization workflows, allergen extract sourcing, biologic prior auth, in-office vs sublingual immunotherapy. Generic clinical claims signal that you do not know the specialty, and community allergists notice immediately. Specificity is credibility.

Skipping the ACAAI ecosystem after the show. ACAAI runs regional meetings, online education, and a full member journal cycle. Vendors who follow up with sponsorship of regional meetings, contributed content, and ACAAI-aligned thought leadership compound the value of a single Annual Scientific Meeting investment over years.

Should You Exhibit at ACAAI in 2026?

Yes, if you sell allergy diagnostics, immunotherapy delivery, allergen extracts, spirometry, epinephrine auto-injectors, biologics for asthma or atopic disease, or practice management software. Community allergists are a tightly defined buying audience with high purchase authority and short decision timelines, and ACAAI is the most efficient way to put 60–100 named practices in front of your sales team in five days. Pair the meeting with a focused conference marketing ROI framework and the math usually clears even for first-time exhibitors.

No, if your audience is academic researchers, clinical trial KOLs, or hospital-based allergy and immunology programs. AAAAI is the better fit for those audiences. ACAAI is a community-practice show, and the floor traffic will not produce qualified pipeline for academic-targeted products no matter how good your booth is.

If you're undecided, run the math the way our team does for clients: estimate the all-in cost of exhibiting (typically $25K–$50K for a credible 10x10 or 10x20 presence including travel, booth, freight, and staffing), divide by your average community-practice deal size and gross margin, and ask whether eight to twelve signed practices in the next 12 months would justify the investment. For most allergy-focused vendors, the answer is yes — but only if pre-show meeting booking and post-show follow-up discipline is real, not aspirational.